New drug duo takes on Hard-to-Treat breast cancer
Disease control
Ongoing
This early-stage trial tests a new drug called OP-1250 combined with an approved targeted therapy, palbociclib, in 60 adults with advanced or metastatic HR-positive, HER2-negative breast cancer. The goal is to find the safest dose and see if the combination can slow tumor growth.…
Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC